(3-amino-4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone | 701910-49-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-amino-4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone
• 英文别名: (3-Amino-4-methoxyphenyl)-(3,4,5-trimethoxyphenyl)methanone
• CAS: 701910-49-8
• 化学式: C₁₇H₁₉NO₅
• 分子量: 317.342
• InChiKey: DYUQYMALNRVYFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3-amino-4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone 在 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以62%的产率得到2-Methoxy-5-[(3,4,5-trimethoxyphenyl)methyl]aniline
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 3-Aminobenzophenones as Antimitotic Agents

  摘要：

  A new series of 3-aminobenzophenone compounds as potent inhibitors of tubulin polymerization was discovered based on the mimic of the aminocombretastatin molecular skeleton. Lead compounds 5 and 11, with alkoxy groups at the C-4 position of B-ring, were potent cytotoxic agents and inhibitors of tubulin polymerization through the binding to the colchicine-binding site of tubulin. The corresponding antitubulin activities of 5 and 11 were similar to or greater than combretastatin A-4 and AVE-8063. Replacement of the methoxy group with a chloro group in the B ring of aminobenzopheneones (3, 8, and 9) caused drastic decrease in cytotoxic and antitubulin activity except in compounds 4 and 10, which could result from a unique alignment between chloro and amino groups located at the para position to each other. SAR information revealed that introduction of an amino group at the C-3 position in B ring of benzophenones, in addition to a methoxy group at the C-4 position, plays an important role for maximal cytotoxicity.

  DOI：

  10.1021/jm0305974
• 作为产物：
  描述：

  3-硝基-4-甲氧基苯甲醛 在 盐酸 、 重铬酸吡啶 、 铁粉 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 溶剂黄146 为溶剂， 反应 10.17h， 生成 (3-amino-4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone
  参考文献：
  名称：

  肉桂连接二苯甲酮杂化蛋白作为微管蛋白聚合抑制剂和凋亡诱导剂的合成及生物学评价

  摘要：

  合成了一类新的杂合分子，其包含与二苯甲酮连接的肉桂酰胺亚基作为微管蛋白聚合的抑制剂，并评估了其抗癌潜力。这些杂种显示出抗癌活性，IC 50值为0.06至16.3μM。肉桂基亚基上具有氟和三氟甲基的化合物4f和4g对IC 50表现出显着的细胞毒性分别针对HeLa细胞株的取值分别为0.06和0.09μM。这些化合物在细胞周期的G2 / M期表现出细胞周期停滞，并抑制微管蛋白聚合，随后激活caspase-3活性和凋亡性细胞死亡。进一步的体外微管蛋白聚合试验表明，化合物4f和4g的微管蛋白抑制水平与2a相当。此外，Hoechst 33258染色和DNA片段化分析表明，这些化合物通过凋亡诱导细胞死亡。总的来说，当前的研究表明，通过靶向微管蛋白，二苯甲酮连接的肉桂酰胺亚基共轭物作为具有希望的抗癌药物具有G2 / M阻滞和凋亡诱导能力。

  DOI：

  10.1016/j.bmcl.2014.03.076

文献信息

• Isocombretastatins A: 1,1-Diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds
  作者：Raquel Álvarez、Concepción Álvarez、Faustino Mollinedo、Beatriz G. Sierra、Manuel Medarde、Rafael Peláez

  DOI：10.1016/j.bmc.2009.07.012

  日期：2009.9.1

  N-methyl- and N-ethyl-5-indolyl analogues of combretastatin A-4. Analogues with a 2,3,4-trimethoxyphenyl ring instead of the 3,4,5-trimethoxyphenyl ring have also been prepared. The isocombretastatins A strongly inhibit tubulin polymerization and are potent cytotoxic compounds, some of them with IC50s in the nanomolar range. This new family of tubulin inhibitors shows higher or comparable potency when compared

  异combretastatins A是康美他汀A的1,1-二芳基乙烯异构体。我们合成了combrestastatin A-4，脱氧康布他汀A-4、3-氨基-脱氧康布他汀A-4（AVE-8063），萘基康布他汀A和N-甲基-和康布雷他汀A-4的N-乙基-5-吲哚基类似物。还已经制备了具有2,3,4-三甲氧基苯基环而不是3,4,5-三甲氧基苯基环的类似物。异combretastatins A强烈抑制微管蛋白聚合，并且是有效的细胞毒性化合物，其中一些具有IC 50在纳摩尔范围内。与酚他汀或康维他汀类似物相比，这个新的微管蛋白抑制剂家族显示出更高或相当的效力。这些结果表明，具有双芳基双取代的一个碳桥可以成功地替代康美他汀的两个碳桥，并且苯他汀类的羰基对于高效能并不是必不可少的。
• NOVEL BENZOPHENONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF
  申请人：Kamal Ahmed

  公开号：US20100174074A1

  公开（公告）日：2010-07-08

  Disclosed herein are benzophenone hybrids with potent anticancer activities and processes for creation of the same.

  本文披露了具有强烈抗癌活性的苯甲酮杂化物以及其制备过程。
• Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands
  作者：Alina Ghinet、Xavier Thuru、Emilie Floquet、Joëlle Dubois、Amaury Farce、Benoît Rigo

  DOI：10.1016/j.bioorg.2020.103643

  日期：2020.3

  The majority of cancers detected every year are treated with anti-cancer compounds. Unfortunately, many tumors become resistant to antineoplastic drugs. One option is to use cocktails of compounds acting on different targets to try to overcome the resistant cells. This type of approach can produce good results, but is often accompanied by a sharp increase of associated side effects.The strategy presented herein focuses on the use of a single compound acting on two different biological targets enhancing potency and lowering the toxicity of the chemotherapy. In this light, the approach presented in the current study involves the dual inhibition of human pyruvate dehydrogenase kinase-1 (PDHK1) and tubulin polymerization using mono-, di- and tri-chloroacetate-loaded benzophenones and benzothiophenones.Synthesized molecules were evaluated in vitro on tubulin polymerization and on pyruvate dehydrogenase kinase 1. The cell cycle distribution after treatment of DA1-3b leukemic cells with active compounds was tested.Twenty-two benzo(thio)phenones have been selected by the National Cancer Institute (USA) for evaluation of their anti-proliferative potential against NCI-60 cancer cell lines including multidrug-resistant tumor cell lines. Seventeen molecules proved to be very effective in combating the growth of tumor cells exhibiting inhibitory activities up to nanomolar range.The molecular docking of best antitumor molecules in the study was realized with GOLD in the tubulin and PDHK1 binding sites, and allowed to understand the positioning of active molecules.Chloroacetate-loaded benzo(thio)phenones are dual targeted tubulin- and pyruvate dehydrogenase kinase 1 (PDHK1)-binding antitumor agents and exhibited superior antitumor activity compared to non-chlorinated congeners particularly on leukemia, colon, melanoma and breast cancer cell lines.
• US8394954B2
  申请人：——

  公开号：US8394954B2

  公开（公告）日：2013-03-12